You are now leaving helsinn.com

Please click 'Continue to external site' if you want to continue.

Pipeline

We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes therapies aimed at providing new solutions in cancer care and rare diseases where no options currently exist, with a goal to help lift the burden of cancer for patients.

Robust R&D Pipeline with significant potential

Near-term and long-term pipeline, securing launches over the coming years.

Cancer Therapeutics

Infigratinib2

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
2nd Line Cholangiocarcinoma3
1st Line Cholangiocarcinoma
Adjuvant Urothelial Cancer

HM064

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Solid Tumors with RET Abnormalities

GPX4 inhibitor5

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Multiple tumors

Cancer Supportive Care

Fosnetupitant IV

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory

Fosnetupitant - Palonosetron

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Pediatric CINV6

Fosnetupitant - Palonosetron IV

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
China - CINV6,7

Anamorelin8

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Cancer Anorexia-Cachexia in NSCLC9 patients
China – Cancer Anorexia-Cachexia in NSCLC9 patients

Other

HM04

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Ghrelin Receptor Antagonist - Prader-Willi Syndrome

HM0110

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Ghrelin Receptor Agonist

Notes

The safety and efficacy of the product candidates in the above table have not been established. There is no guarantee that they will receive health authority approval or become commercially available in any country for the uses being investigated.

  1. Regulatory: Marketing authorization application upcoming or submitted
  2. lnfigratinib is developed globally by Helsinn Healthcare SA in all fields of use except for skeletal dysplasias and except in the following territories: Mainland China, Hong Kong and Macau
  3. Approved in U.S., Canada and Australia
  4. HM06 is co-developed by Helsinn Healthcare SA and Taiho Pharmaceutical Co. Ltd.
  5. GPX4 inhibitor is co-developed by Helsinn Healthcare SA and BridgeBio Pharma, Inc.
  6. Chemotherapy-Induced Nausea and Vomiting
  7. Approved in multiple territories, including USA and EU
  8. Approved in Japan
  9. Non-Small Cell Lung Cancer
  10. HM01 is developed by Helsinn’s partner, AnaCardio